Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Rapidly produced SAM ® vaccine against H7N9 influenza is immunogenic in mice

by Maione, Domenico , Geall, Andrew J , Casini, Daniele , De Gregorio, Ennio , Brazzoli, Michela , Urano, Jun , Buccato, Scilla , Hekele, Armin , Archer, Jacob , Caiazza, Nicky C , Craig Venter, J , Palladino, Giuseppe , Mandl, Christian W , Qi, Zhi-Qing , Ulmer, Jeffrey B , Bonci, Alessandra , Otten, Gillis R , Gao, George F , Hubby, Bolyn , Gibson, Daniel G , Brito, Luis A , Rappuoli, Rino , Bertholet, Sylvie , Mason, Peter W , Settembre, Ethan C , Gill, John E , Dormitzer, Philip R , Shu, Yuelong

in Original

2013

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Rapidly produced SAM ® vaccine against H7N9 influenza is immunogenic in mice

in Original

2013

Confirm

Do you wish to request the book?

Rapidly produced SAM ® vaccine against H7N9 influenza is immunogenic in mice

in Original

2013

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Rapidly produced SAM ® vaccine against H7N9 influenza is immunogenic in mice

Maione, Domenico,

Geall, Andrew J,

Casini, Daniele,

De Gregorio, Ennio,

Brazzoli, Michela,

Urano, Jun,

Buccato, Scilla,

Hekele, Armin,

Archer, Jacob,

Caiazza, Nicky C,

Craig Venter, J,

Palladino, Giuseppe,

Mandl, Christian W,

Qi, Zhi-Qing,

Ulmer, Jeffrey B,

Bonci, Alessandra,

Otten, Gillis R,

Gao, George F,

Hubby, Bolyn,

Gibson, Daniel G,

Brito, Luis A,

Rappuoli, Rino,

Bertholet, Sylvie,

Mason, Peter W,

Settembre, Ethan C,

Gill, John E,

Dormitzer, Philip R,

Shu, Yuelong

2013

Overview

The timing of vaccine availability is essential for an effective response to pandemic influenza. In 2009, vaccine became available after the disease peak, and this has motivated the development of next generation vaccine technologies for more rapid responses. The SAM(®) vaccine platform, now in pre-clinical development, is based on a synthetic, self-amplifying mRNA, delivered by a synthetic lipid nanoparticle (LNP). When used to express seasonal influenza hemagglutinin (HA), a SAM vaccine elicited potent immune responses, comparable to those elicited by a licensed influenza subunit vaccine preparation. When the sequences coding for the HA and neuraminidase (NA) genes from the H7N9 influenza outbreak in China were posted on a web-based data sharing system, the combination of rapid and accurate cell-free gene synthesis and SAM vaccine technology allowed the generation of a vaccine candidate in 8 days. Two weeks after the first immunization, mice had measurable hemagglutinin inhibition (HI) and neutralizing antibody titers against the new virus. Two weeks after the second immunization, all mice had HI titers considered protective. If the SAM vaccine platform proves safe, potent, well tolerated and effective in humans, fully synthetic vaccine technologies could provide unparalleled speed of response to stem the initial wave of influenza outbreaks, allowing first availability of a vaccine candidate days after the discovery of a new virus.

Share this book

Add to My Shelf

Publisher

Taylor & Francis Ltd,Nature Publishing Group

Subject

Original